[go: up one dir, main page]

AR094912A1 - Vacuna contra el virus de la leucemia bovina - Google Patents

Vacuna contra el virus de la leucemia bovina

Info

Publication number
AR094912A1
AR094912A1 ARP140100623A ARP140100623A AR094912A1 AR 094912 A1 AR094912 A1 AR 094912A1 AR P140100623 A ARP140100623 A AR P140100623A AR P140100623 A ARP140100623 A AR P140100623A AR 094912 A1 AR094912 A1 AR 094912A1
Authority
AR
Argentina
Prior art keywords
nucleic acids
vectors
recombinant
blv
viruses
Prior art date
Application number
ARP140100623A
Other languages
English (en)
Inventor
Willems Luc
Trono Karina
Original Assignee
Inst Nac De Tecnología Agropecuaria
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nac De Tecnología Agropecuaria, Univ Liege filed Critical Inst Nac De Tecnología Agropecuaria
Publication of AR094912A1 publication Critical patent/AR094912A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14061—Methods of inactivation or attenuation
    • C12N2740/14062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Virus recombinantes de la leucemia bovina que tienen un fenotipo atenuado y comprenden una combinación de al menos dos mutaciones específicas. También se proveen ácidos nucleicos recombinantes que codifican dichos virus, vectores que comprenden dichos ácidos nucleicos, y células hospedadoras que comprenden dichos ácidos nucleicos o vectores. Los virus BLV recombinantes atenuados, ácidos nucleicos recombinantes, vectores y células hospedadoras permiten la preparación de vacunas mejoradas, en particular vacunas adecuadas para el tratamiento profiláctico de enfermedades asociadas a BLV en sujetos. Adicionalmente se proveen métodos para tratar enfermedades asociadas a BLV en sujetos y composiciones farmacéuticas adecuadas para el uso en estos métodos.
ARP140100623A 2013-02-27 2014-02-27 Vacuna contra el virus de la leucemia bovina AR094912A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13156921 2013-02-27

Publications (1)

Publication Number Publication Date
AR094912A1 true AR094912A1 (es) 2015-09-09

Family

ID=47749713

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100623A AR094912A1 (es) 2013-02-27 2014-02-27 Vacuna contra el virus de la leucemia bovina

Country Status (7)

Country Link
US (2) US10029006B2 (es)
EP (1) EP2961425B1 (es)
AR (1) AR094912A1 (es)
BR (1) BR112015020604B1 (es)
CA (1) CA2901508A1 (es)
MX (1) MX358118B (es)
WO (1) WO2014131844A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113817A1 (en) * 2018-10-09 2020-04-16 The University Of North Carolina At Chapel Hill Regulated gene editing system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2396978C1 (ru) 2009-03-05 2010-08-20 Федеральное государственное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Способ профилактики развития лейкоза крупного рогатого скота

Also Published As

Publication number Publication date
MX2015011064A (es) 2016-03-01
MX358118B (es) 2018-08-06
EP2961425B1 (en) 2018-05-30
WO2014131844A1 (en) 2014-09-04
US11154611B2 (en) 2021-10-26
US10029006B2 (en) 2018-07-24
CA2901508A1 (en) 2014-09-04
EP2961425A1 (en) 2016-01-06
US20160045593A1 (en) 2016-02-18
BR112015020604A2 (pt) 2017-10-10
BR112015020604B1 (pt) 2023-11-21
US20190000963A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
EP4233898A3 (en) Influenza mrna vaccines
CL2017002731A1 (es) Adenovirus oncolítico que codifica una proteína b7
CO2018007203A2 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
AR108630A1 (es) Virus vaccinia modificados genéticamente
PH12013502322A1 (en) Hendra and nipah virus g glycoprotein immunogenic compositions
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX373792B (es) Coronavirus.
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
WO2016144564A9 (en) Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
PH12015500499A1 (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
FI3656395T3 (fi) Menetelmiä ja koostumuksia suojaavan immuniteetin aikaansaamiseksi filovirusinfektiota vastaan
AR101814A1 (es) Partícula de tipo virus flavivirus
MX2018004016A (es) Vacunas de particulas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos.
BR112018072372A2 (pt) combinações de vacina terapêutica contra o hpv
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
MX377258B (es) Composiciones de vectores poxvirus y su uso para inducir una respuesta inmunitaria.
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
SG11201706342PA (en) An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
ZA202003070B (en) Lassa vaccine
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
EP4226936A3 (en) Non-neuroinvasive viruses and uses thereof
AR094912A1 (es) Vacuna contra el virus de la leucemia bovina
WO2014152271A8 (en) Viral proteins as immunomodulatory agents and vaccine components

Legal Events

Date Code Title Description
FG Grant, registration